Abbott stock (NYSE: ABT) currently trades at $105 per share, 25% below its peak level of over $140 seen in December 2021. In comparison, its peer Boston Scientific stock (NYSE: BSX) has seen a nearly 90% rise over this period.
In the latest trading session, Boston Scientific (BSX) closed at $77.01, marking a +0.01% move from the previous day.
Boston Scientific (BSX) secures CE Mark for the DBS image-guided programming software, Vercise Neural Navigator 5.
U.S. markets continued to set all-time highs in June, with record-breaking stocks boosting major indices to new records last week. Even the traditionally slower DJIA logged two consecutive record peaks in two days.
Boston Scientific (BSX) closed the most recent trading day at $76.71, moving -1.29% from the previous trading session.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
This acquisition is expected to enhance Boston Scientific's (BSX) market position and revenue streams in North America and Europe.
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, RMD, LNTH and HAE are well-poised to gain from the favorable factors.
The latest trading day saw Boston Scientific (BSX) settling at $76.31, representing a +0.16% change from its previous close.
Shares of Silk Road Medical (SILK) soared in intraday trading Tuesday after Boston Scientific (BSX) announced it was buying the medical device maker for about $1.26 billion.
Tuesday, Boston Scientific Corporation BSX agreed to acquire Silk Road Medical Inc SILK for $27.50 in cash per share, representing an equity value of approximately $1.26 billion.
Boston Scientific will pay $27.50 a share, or $1.16 billion, for Silk Road Medical.